The majority of CML patients in Canada today are treated with oral tyrosine kinase inhibitors (TKI’s). There are currently (2015) seven TKI’s approved by health Canada for the treatment of CML patients in Canada.
Click on the links below to learn the approved indications for the drugs use in CML and, in some cases, in other diseases in Canada
